<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440528</url>
  </required_header>
  <id_info>
    <org_study_id>29112017NCRRT</org_study_id>
    <nct_id>NCT03440528</nct_id>
  </id_info>
  <brief_title>Using of Irradiated Amnion Dressing for the Treatment of Skin Ulcer</brief_title>
  <official_title>Using of Irradiated Amnion Dressing for the Treatment of Skin Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egyptian Atomic Energy Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egyptian Atomic Energy Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the using of a commercial product of dried human amniotic membrane sterilized by
      gamma irradiation for the treatment of skin ulcer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dried human amniotic membrane patches were obtained from National center for radiation
      research and technology, Egypt, under commercial name REGE pro.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Size of ulcer</measure>
    <time_frame>2 week</time_frame>
    <description>REGE pro decreased size of ulcer after second treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain</measure>
    <time_frame>1 week</time_frame>
    <description>Patients response revealed reduction of pain at the time of application. One week post application, a questionnaire were collected from patients; about 95% of them ensured that pain was controlled.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complete curring</measure>
    <time_frame>4 to 10 weeks</time_frame>
    <description>REGE pro healed ulcer after 4 to 10 weeks. The improvement of ulcer was observed by photographs taken before and each week post application.</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from scarring</measure>
    <time_frame>10 weeks</time_frame>
    <description>It was observed that the using of REGE pro prevent any scar formation in all applied patients.</description>
  </other_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Ulcer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study is based on randomized selection of 3 types of ulcer ( diabetic foot ulcer, post
        operative ulcer and ultrasonic ulcer)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients have unhealing ulcer

        Exclusion Criteria:

          -  must stop other line of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nashwa K Radwan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amniotic tissue lab</name>
      <address>
        <city>Cairo</city>
        <zip>29</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 30, 2017</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Egyptian Atomic Energy Authority</investigator_affiliation>
    <investigator_full_name>Nashwa Radwan</investigator_full_name>
    <investigator_title>Lecture of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Skin ulcer, Human amniotic membrane, Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

